Log in or Sign up for Free to view tailored content for your specialty!
Steatohepatitis/Metabolic Liver Disease News
Pegozafermin improves stage 4 fibrosis, noninvasive markers in MASH patients
BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.
Aldafermin 3 mg significantly reduced Enhanced Liver Fibrosis score in MASH
BOSTON — Treatment with aldafermin 3 mg appeared to be well-tolerated and significantly reduced Enhance Liver Fibrosis score after 48 weeks among patients with metabolic dysfunction-associated steatohepatitis, according to a presenter.
Log in or Sign up for Free to view tailored content for your specialty!
ENLIVEN extension topline data: Pegozafermin sustains ‘robust benefits’ in NASH at week 48
Topline findings from an extension of the phase 2b ENLIVEN trial showed that pegozafermin sustained improvements in fibrosis and disease resolution for patients with nonalcoholic steatohepatitis at 48 weeks, 89bio announced.
Up to 67% of patients achieve MASH resolution at 36 weeks with efruxifermin
BOSTON — Treatment with efruxifermin resulted in “clinically meaningful” but not yet statistically significant benefit at 36 weeks in cirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to late-breaking data.
Retatrutide 12 mg resolved steatosis in more than 90% of patients with obesity, MASLD
BOSTON — Treatment with retatrutide at 8 mg and 12 mg resulted in substantial reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease, according to a presenter at The Liver Meeting.
High ultra-processed food intake linked to increased MASLD risk in adolescents, adults
Increased consumption of ultra-processed foods was associated with higher odds of developing metabolic dysfunction-associated steatotic liver disease in both adolescents and adults, according to research presented at The Liver Meeting.
Low-dose aspirin ‘potential therapeutic option’ for MASLD, markedly reduces steatosis
BOSTON — Low-dose aspirin significantly reduced steatosis in patients with metabolic dysfunction-associated steatotic liver disease and improved markers of liver inflammation and fibrosis, according to data presented at The Liver Meeting.
VIDEO: TERN-501 ‘could be a best-in-class molecule’ alone, as combination therapy for MASH
BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.
‘Significant differences’ reported by race, ethnicity in transplant rates for MASH-HCC
BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.
MASH resolution without worsening fibrosis boosts 15-year survival after bariatric surgery
BOSTON — Resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis was linked to long-term survival after bariatric surgery, similar to that of patients without baseline MASH, according to a presenter.
-
Headline News
‘Tide is turning’: STI epidemic shows signs of slowing, CDC says
November 12, 20242 min read -
Headline News
Q&A: Intuitive eating can help people with diabetes improve their relationship with food
November 13, 20246 min read -
Headline News
Teens vape nicotine to help them relax, survey finds
November 12, 20242 min read
-
Headline News
‘Tide is turning’: STI epidemic shows signs of slowing, CDC says
November 12, 20242 min read -
Headline News
Q&A: Intuitive eating can help people with diabetes improve their relationship with food
November 13, 20246 min read -
Headline News
Teens vape nicotine to help them relax, survey finds
November 12, 20242 min read